341 related articles for article (PubMed ID: 20675931)
1. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].
Katagiri T
Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931
[TBL] [Abstract][Full Text] [Related]
2. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N
Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033
[TBL] [Abstract][Full Text] [Related]
3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
4. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
[TBL] [Abstract][Full Text] [Related]
5. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
6. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
7. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
[TBL] [Abstract][Full Text] [Related]
8. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
[TBL] [Abstract][Full Text] [Related]
9. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
12. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
13. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Luo Y; Alsamarah A; Zhang K; Hao J
Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
[TBL] [Abstract][Full Text] [Related]
14. Genetic abnormalities in fibrodysplasia ossificans progressiva.
Miao J; Zhang C; Wu S; Peng Z; Tania M
Genes Genet Syst; 2012; 87(4):213-9. PubMed ID: 23229308
[TBL] [Abstract][Full Text] [Related]
15. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
[TBL] [Abstract][Full Text] [Related]
16. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
17. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
18. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
[TBL] [Abstract][Full Text] [Related]
19. Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.
de Gorter DJ; Jankipersadsing V; Ten Dijke P
Curr Pharm Des; 2012; 18(27):4087-92. PubMed ID: 22630080
[TBL] [Abstract][Full Text] [Related]
20. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]